<DOC>
	<DOCNO>NCT01241344</DOCNO>
	<brief_summary>The primary objective study evaluate safety efficacy preemptive treatment CMX001 versus placebo prevention AdV disease recipient HSCT asymptomatic AdV viremia .</brief_summary>
	<brief_title>The Adv Halt Trial</brief_title>
	<detailed_description />
	<mesh_term>Adenoviridae Infections</mesh_term>
	<criteria>1 . Males females ≥ 3 month ≤ 75 year age . 2 . Subjects receive allogeneic HSCT . 3 . Positive serum AdV PCR ( &gt; 100 copies/mL ) measure central laboratory . 4 . Subject guardian ( ) willing comply protocol . 5 . Subject guardian ( ) willing able understand inform consent/assent . 6 . Females childbearing potential must negative pregnancy test ( serum betahCG ) sexually active female must use reliable medically approve method contraception throughout study . Sexually active male procreation potential must able willing use reliable medically approve contraceptive method throughout study . At least one barrier method contraception must use , subject procreation potential . 1 . Subject possible , probable , definitive AdV disease . See Appendix 2Error ! Reference source find . definition criterion outline possible , probable definitive AdV disease . 2 . Suspected gut graft versus host disease ( GVHD ) biopsyproven ( subject biopsy perform may include study ) . 3 . Subject eGFR ≤ 30 mL/minute currently dialysis . 4 . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 10 time ULN , conjugate bilirubin &gt; 5 time upper limit normal ( ULN ) . 5 . Subject mucositis prevent ingestion oral medication . 6 . Subject Human Immunodeficiency Virus ( HIV ) antibody positive , base upon available medical record . 7 . Subject ocular hypotony , uveitis , retinitis intraocular pathology would predispose subject one condition . 8 . Subject participate investigational drug study expose investigational drug within 14 day enrollment . 9 . Is pregnant breastfeed intend conceive course study , include followup period drug discontinuation . 10 . Known immunologic hypersensitivity CDV CMX001 drug excipients . 11 . History illicit drug use alcohol abuse within previous 6 month . 12 . Any medical condition , opinion Investigator , might interfere subject 's participation study , pose add risk subject , confound assessment subject ( e.g . severe cardiovascular , central nervous system ( CNS ) pulmonary disease ) . 13 . Subject receive CMX001 , CDV , ribavirin , leflunomide within previous 14 day .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Adv</keyword>
	<keyword>Hematopoeitic Stem cell Transplant</keyword>
	<keyword>HSCT</keyword>
</DOC>